Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Apr;68(4):465-70.
doi: 10.1111/ijcp.12374. Epub 2014 Mar 3.

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

G Adler  1 , B Mueller, K Articus
Affiliations
Observational Study

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

G Adler et al. Int J Clin Pract. 2014 Apr.

Abstract

Background: Rivastigmine is the only cholinesterase inhibitor (ChEI) available as transdermal patch. The patch was developed to improve gastrointestinal tolerability and treatment adherence to higher dosages as compared with oral medication. Preferences of patients and caregivers for the patch were reported; however, neither patient compliance nor caregiver burden has yet been measured under routine practice conditions.

Methods: This was a prospective, multi-centre, observational study in patients with Alzheimer's disease treated with rivastigmine patch in Germany. To compare the transdermal with oral dosage forms, physicians were asked to enrol patients who recently switched from oral to transdermal medication. Beyond effectiveness and tolerability, outcome measures were drug adherence evaluated by the Morisky questionnaire, and caregiver burden, measured as the daily time expenditure for dressing the patient, controlling appearance and administration of medication.

Results: In total, 1104 outpatients (57.5% female gender; mean age 77 ± 7 years) were enrolled in 220 sites. After 6 months of treatment, 67.5% of patients had an improved Clinical Global Impression and the Mini-Mental State Examination score increased from 19.0 ± 5.1 to 20.0 ± 5.2 (p < 0.001); 84.1% of patients were still on treatment, 64.6% on the target dose of 9.5 mg/day. Compliance and patient satisfaction with therapy continuously increased over the study period and average time savings of caregivers added up to 20 min/day. In general, tolerability was deemed good and there were no unexpected adverse events.

Conclusions: Transdermal rivastigmine is an effective treatment alternative, which may improve adherence and treatment satisfaction of the patient and relieve the caregiver. Controlled parallel-group trials are warranted.

Clinical trials registration: none (observational study).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effectiveness: change in CGI over 6 months
Figure 2
Figure 2
Patient satisfaction: (A) reasons for preference of the patch and (B) patient satisfaction with current antidementia therapy
Figure 3
Figure 3
(A) Patient compliance, based on the Morisky Questionnaire and (B) caregiver burden
See this image and copyright information in PMC

Comment in

References

    1. Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv. 2011;8:581–603. - PubMed
    1. Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2011;26:65–71. - PMC - PubMed
    1. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456–67. - PubMed
    1. Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:341–53. - PubMed
    1. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs. 2011;71:1209–31. - PubMed

Publication types